Clinical Trial Update: An Evaluation of the Pharmacokinetics and Pharmacodynamics of AP09004 in Patients With Parkinson's Disease [Phase 2]

View source ↗

Summary

Phase 2 pharmacokinetic and pharmacodynamic evaluation of the investigational drug AP09004 in patients with Parkinson's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• AP09004

Snippet

Sponsor: Intec Pharma Ltd. | Conditions: Parkinson's Disease | Phase 2 | Status: COMPLETED